Brain Dead Diagnosis and Treatment Market will Boost at a strong CAGR of 7% during the forecast period 2017-2023

Pune, India, December 2017 /MRFR Press Release/- Market Research Future has a half-cooked research report on the global brain dead diagnosis and treatment.

Market Highlights

An individual suffering from brain death cannot be cured as such but treatments can be provided to prevent any further physical or neurological damage. However, depending on the cause of brain death, patients are normally declared dead and opted for organ donation. A person declared brain dead are less likely to awaken as the whole body ceases to function and undergo a state of hibernation or shut down.

The growth promoting factors of the global brain dead diagnosis and treatment market are, increase in the number of accidents and resultant brain surgerical procedures, and increasing penetration of brain speciality hospitals and healthcare insurance over the forecast period.

The diagnosis of brain death needs to be rigorous, in order to be certain that the condition is irreversible. One diagnostic technique such as CT angiography is not sufficient test to conclude the diagnosis. A radionuclide cerebral blood flow scan showcasing complete absence of intracranial blood flow must be considered with other exams, temporary swelling of the brain, particularly within the first 3 days, can lead to a false test on a patient that might have the chance to recover with more time.

There are numerous causes of brain dead such as traumatic brain injuries and are often caused by accidents or acts of violence. The increasing government support for research & development, changing lifestyle, and rapid development in technology will fuel the market growth during the forecast period. On the other hand, higher cost of the treatment procedure may slow the market growth during the review period.

Regional Analysis

Global brain dead diagnosis and treatment consists of regions namely Americas, Europe, Asia Pacific, and the Middle East.

North America dominated the global brain dead diagnosis and treatment market. Although in the United States a flat EEG test is not required to certify death, it is considered to have confirmatory value. The exams must show complete and irreversible absence of brain function The patient must be free of drugs that can suppress brain activity if the diagnosis is to be made on EEG criteria.

Europe holds the second largest share of the global brain dead diagnosis & treatment market. The brain electrical activity can stop completely, or drop to such a low level as to be undetectable with most equipment. An EEG will therefore be flat, though this is sometimes also observed during deep anesthesia or cardiac arrest. In the UK it is not considered to be of value because any continuing activity it might reveal in parts of the brain above the brain stem is held to be irrelevant to the diagnosis of death on the Code of Practice criteria. The growing public awareness will boost the adoption of these devices in the Europe market.

Asia Pacific is the fastest growing coma diagnosis & treatment market across the globe. The increasing healthcare expenditure, and government initiatives for research & development will drive the market in China and India over the period. The Middle East and Africa hold the least share of the global brain dead diagnosis & treatment market due to limited availability of medical facilities.

Segmentation

The brain dead diagnosis, and treatment market is segmented on the basis of is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of diagnosis, it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI), electroencephalography (EEG), radionuclide angiography, cerebral arteriography, nuclear brain scanning, and transcranial doppler ultrasonography

On the basis of treatment, it is segmented into medical treatment, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Key Players

Some of key the players in the global brain dead diagnosis and treatment market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others.

 Access Report Details @ https://www.marketresearchfuture.com/reports/brain-dead-diagnosis-and-treatment-market-4997

 About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. 

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. 

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

 Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com